Tag: cardiovascular risk
Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia
1. A significantly greater proportion of patients receiving 2-3 lipid lowering medications achieved LDL-cholesterol targets compared to those receiving monotherapy. ...
Long-term enzyme-inducing antiseizure medication use associated with elevated hazard of incident cardiovascular disease
1. In this cohort study, there was a dose-dependent association between enzyme-inducing antiseizure medication use and an elevated hazard of ...
Cycling is associated with reduced all-cause and cardiovascular disease mortality in individuals with diabetes
1. Time spent cycling was associated with lower all-cause and cardiovascular disease-specific mortality in this multicenter European cohort study of ...
Coronary artery calcium scoring associated with significant improvements in atherosclerotic cardiovascular disease reclassification when guiding statin therapy
1. The use of coronary artery calcium scoring was associated with significant improvements in the reclassification and discrimination of incident ...
Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention
1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with ...
Conventional cardiovascular risk assessments may overestimate risk in populations with widespread diabetes screening guidelines
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New ...
Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors
1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic ...
Normotensive patients with elevated cardiovascular risk may benefit from antihypertensive pharmacotherapy
1. Regardless of cardiovascular disease history and baseline blood pressure, a 5 mmHg reduction in systolic blood pressure reduced relative ...
ST-elevation myocardial infarctions in the absence of standard modifiable cardiovascular risk factors may have worse outcomes
1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first ...
